Titlebook: Comprehensive Cardiovascular Medicine in the Primary Care Setting; Peter P. Toth,Christopher P. Cannon Textbook 2019Latest edition Springe

EVADE

restrain

Stem Cells and Cancer Stem Cellsdominal adiposity and its associated metabolic risk factors have fueled speculation that cardiovascular disease will become the leading cause of mortality worldwide by 2020 (Murray and Lopez, Lancet 349:1498–1504, 1997). Increasing interest has focused on the development of new systemic biomarkers t

angina-pectoris

recede

BORE

的阐明

Mehmet Tokaç,Tahsin Murad AktanChest pain represents a wide spectrum of disease, from benign to life-threatening conditions. The primary care provider has an essential role in the initial evaluation of such patients with a focus on a quick rule out of potential life-threatening conditions and further appropriately triaging the pa

armistice

Ung Kim MD, PhD,Dong-Gu Shin MD, PhDive coronary artery disease (CAD) (Patel et al., N Engl J Med 362:886–895, 2010). Many times, chest pain in these patients may be attributed to non-cardiac causes, such as musculoskeletal pain or pathology in the gastrointestinal or pulmonary systems. However, myocardial small vessel disease, also c

gait-cycle

Stem Cells and Cancer Stem Cellses ST elevation myocardial infarction (STEMI). Combined, UA and NSTEMI are known as non-ST elevation acute coronary syndrome (NSTE-ACS). Recent estimates suggest that 1.14 million hospitalizations occurred for ACS events in 2010 in the United States, with 813,000 for myocardial infarction. Of those

Intervention

Stem Cells and Cancer Stem Cellsre were 750,000 Americans with acute myocardial infarction (MI) in 2016 (American Heart Association, Circulation 133:e38–e360, 2016). Approximately 30–45% of these were STEMI. Excellent societal guideline recommendations exist for STEMI care (O’Gara et al, J Am Coll Cardiol 61:e78–e140, 2013; Levine

Anticlimax

Mukesh Kumar Gupta,Hoon Taek Lee field of interventional cardiology and ushered in a new era of coronary revascularization. Percutaneous coronary transluminal angioplasty (PTCA) was positioned to serve as an alternative and complement to coronary artery bypass grafting (CABG) and optimal medical therapy. As in many medical fields,